用(R)-[11C]PAQ PET评估MMTV-PyMT乳腺癌小鼠模型的治疗反应
在MMTV-PyMT乳腺癌小鼠模型中,比较单用溶媒、鼠源抗VEGFA抗体B20-4.1.1、紫杉醇单药及B20-4.1.1联合紫杉醇治疗后,(R)-[11C]PAQ PET的SUVmax变化与MRI肿瘤体积变化及免疫组化指标的关系。联合组和B20-4.1.1单药组SUVmax显著降低,PTX单药组无显著变化;MRI示仅联合组肿瘤体积显著减小。作者认为结果有前景,但(R)-[11C]PAQ作为疗效预测示踪剂前需进一步研究。
要点
- B20-4.1.1联合紫杉醇组和B20-4.1.1单药组第4天肿瘤(R)-[11C]PAQ SUVmax显著降低。
- 紫杉醇单药组SUVmax无显著变化;仅联合组MRI肿瘤体积显著减小。
- 联合组与溶媒组血管密度有显著差异,各治疗组Ki67阳性信号无显著差异。
核心结论
- 作者认为本研究结果有前景,但在(R)-[11C]PAQ被批准作为癌症治疗反应的预测性放射性示踪剂之前,还需进一步研究。
研究设计与样本
- MMTV-PyMT小鼠分别接受溶媒(VEH)、鼠源抗VEGFA抗体(B20-4.1.1)、紫杉醇(PTX)单药或联合治疗。
- 在基线(第0天)和随访(第4天)用(R)-[11C]PAQ PET测量SUVmean、SUVmax相对变化,并用MRI测量PyMT乳腺肿瘤体积变化。
- 用免疫组化测定肿瘤组织Ki67、VEGFR-2和CD31表达,用非参数统计检验评估示踪剂摄取与治疗反应生物标志物的关系。
主要发现
- B20-4.1.1/PTX联合组和B20-4.1.1单药组第4天肿瘤(R)-[11C]PAQ SUVmax显著降低(分别为p < 0.0005和p < 0.003)。
- PTX单药组SUVmax未见显著变化。
- VEH组与B20-4.1.1/PTX联合组之间、VEH组与B20-4.1.1单药组之间SUVmax变化有显著差异(p < 0.05)。
- MRI示B20-4.1.1/PTX治疗组肿瘤体积显著减小(p < 0.005),其他治疗组未见显著减小。
- B20-4.1.1/PTX联合组与VEH组血管密度有显著差异(p < 0.05),各治疗组间Ki67阳性信号无显著差异;B20-4.1.1/PTX组(R)-[11C]PAQ SUVmax变化与肿瘤体积缩小呈正趋势。
局限性
- 作者指出,在(R)-[11C]PAQ可被批准作为癌症治疗反应的预测性放射性示踪剂之前,还需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The goal of the study was to assess the potential of the vascular endothelial growth factor receptor (VEGFR)-2-targeting carbon-11 labeled (R)-N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-3-piperidinyl)methoxy)-4-quinazolineamine ((R)-[11C]PAQ) as a positron emission tomography (PET) imaging biomarker for evaluation of the efficacy of anticancer drugs in preclinical models. METHODS: MMTV-PyMT mice were treated with vehicle alone (VEH), murine anti-VEGFA antibody (B20-4.1.1), and paclitaxel (PTX) in combination or as single agents. The treatment response was measured with (R)-[11C]PAQ PET as standardized uptake value (SUV)mean, SUVmax relative changes at the baseline (day 0) and follow-up (day 4) time points, and magnetic resonance imaging (MRI)-derived PyMT mammary tumor volume (TV) changes. Expression of Ki67, VEGFR-2, and CD31 in tumor tissue was determined by immunohistochemistry (IHC). Non-parametric statistical tests were used to evaluate the relation between (R)-[11C]PAQ radiotracer uptake and therapy response biomarkers. RESULTS: The (R)-[11C]PAQ SUVmax in tumors was significantly reduced after 4 days in the B20-4.1.1/PTX combinational and B20-4.1.1 monotherapy groups (p < 0.0005 and p < 0.003, respectively). No significant change was observed in the PTX monotherapy group. There was a significant difference in the SUVmax change between the VEH group and B20-4.1.1/PTX combinational group, as well as between the VEH group and the B20-4.1.1 monotherapy group (p < 0.05). MRI revealed significant decreases in TV in the B20-4.1.1/PTX treatment group (p < 0.005) but not the other therapy groups. A positive trend was observed between the (R)-[11C]PAQ SUVmax change and TV reduction in the B20-4.1.1/PTX group. Statistical testing showed a significant difference in the blood vessel density between the B20-4.1.1/PTX combinational group and the VEH group (p < 0.05) but no significant difference in the Ki67 positive signal between treatment groups. CONCLUSIONS: The results of this study are promising. However, additional studies are necessary before (R)-[11C]PAQ can be approved as a predictive radiotracer for cancer therapy response.
引用
- Tegnebratt T, Lu L, Eksborg S, et al. Treatment response assessment with (R)-[11CPAQ PET in the MMTV-PyMT mouse model of breast cancer. EJNMMI Res. 2018. PMID: 29616369. doi:10.1186/s13550-018-0380-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。